Cargando…
Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
BACKGROUND: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by infection with the SARS-CoV-2 virus. Currently, there are three approved vaccines against SARS-CoV-2 in the USA, including two based on messenger RNA (mRNA) technology that has demonstrated high vaccine efficacy. We...
Autores principales: | Fraley, Elizabeth, LeMaster, Cas, Geanes, Eric, Banerjee, Dithi, Khanal, Santosh, Grundberg, Elin, Selvarangan, Rangaraj, Bradley, Todd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310732/ https://www.ncbi.nlm.nih.gov/pubmed/34304742 http://dx.doi.org/10.1186/s12916-021-02055-9 |
Ejemplares similares
-
Cross-reactive antibody immunity against SARS-CoV-2 in children and adults
por: Fraley, Elizabeth, et al.
Publicado: (2021) -
Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination
por: Geanes, Eric S., et al.
Publicado: (2022) -
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Bradley, Todd, et al.
Publicado: (2021) -
Immune cell residency in the nasal mucosa may partially explain respiratory disease severity across the age range
por: Winkley, Konner, et al.
Publicado: (2021) -
High-resolution epigenome analysis in nasal samples derived from children with respiratory viral infections reveals striking changes upon SARS-CoV-2 infection
por: Winkley, Konner, et al.
Publicado: (2021)